Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation
Open Access
- 11 December 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6394-6401
Abstract
Acute kidney injury (AKI) frequently follows hematopoietic cell transplantation (HCT). Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker of AKI in the general population. We evaluated suPAR and its association with AKI requiring dialysis (AKI-D) in patients undergoing allogeneic HCT (alloHCT). Performance of suPAR was compared with serum creatinine (sCr) and neutrophil gelatinase-associated lipocalin (NGAL). Data were obtained from the Blood and Marrow Transplant Clinical Trials Network 1202 cohort, an observational study of 1709 alloHCT recipients. Adults aged ≥18 years with AKI-D after HCT were included. Adults who did not develop AKI were included as controls and matched 1:1. Periodic serum samples (7-90 days) were analyzed for NGAL, suPAR, and sCr. The 1:1 matched case-control groups (n = 62 each) were balanced in demographic variables, except for graft-versus-host disease prophylaxis. The median time from transplant to AKI-D was 2.6 months (range, 0.03-20.39). The day +7 suPAR level after HCT was higher in patients with AKI (median, 2.7 ng/mL) than in controls (2.1 ng/mL; P = .002). In the multivariate analysis, the day +7 suPAR level was associated with the development of AKI-D (P = .009). The area under the curve for the receiver operating characteristic curve for day +7 suPAR levels was 0.75. Neither NGAL nor sCr were associated with AKI-D. Elevated day +7 suPAR levels predicted AKI and lower overall survival (OS). The suPAR level at day +7 after HCT may be an early prognostic factor for the development of AKI-D and OS. Future prospective studies could evaluate this at different stages of AKI. This trial was registered at www.ClinicalTrial.gov as #NCT01879072.Keywords
This publication has 32 references indexed in Scilit:
- Predictive value of suPAR in AKI: a systematic review and meta-analysisClinical and Experimental Nephrology, 2022
- Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury – A systematic reviewClinica Chimica Acta, 2022
- A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703Transplantation and Cellular Therapy, 2020
- Molecular nephrology: types of acute tubular injuryNature Reviews Nephrology, 2019
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis PatientsKidney International Reports, 2018
- suPAR and chronic kidney disease—a podocyte storyPflügers Archiv - European Journal of Physiology, 2017
- Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseNature Medicine, 2016
- Acute kidney injury in HCT: an updateBone Marrow Transplantation, 2016
- The Kidney Effects of Hematopoietic Stem Cell TransplantationAdvances in Chronic Kidney Disease, 2014
- Renal dysfunction in allogeneic hematopoietic cell transplantationKidney International, 2002